Fuller & Thaler Asset Management
TCRT icon

Fuller & Thaler Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Fuller & Thaler Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,273
Closed -$516K – 503
2022
Q1 		$516K Buy
5,273
+20
+0.4% +$2.57K ﹤0.01% 423
2021
Q4 		$859K Buy
+5,253
New +$1.15M 0.01% 405

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Fuller & Thaler Asset Management's TCRT Position: Q2 2022 in Review

Fuller & Thaler Asset Management sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 5,273 shares — an estimated $516K sold.

Fuller & Thaler Asset Management first reported a position in TCRT in Q4 2021 and held it in 2 quarters. The position peaked at $859K in Q4 2021. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Fuller & Thaler Asset Management reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 5,273 Alaunos Therapeutics shares in Q2 2022, an estimated $516K.
  • Fuller & Thaler Asset Management first reported a position in Alaunos Therapeutics in Q4 2021 and held it in 2 quarters.
  • Fuller & Thaler Asset Management's Alaunos Therapeutics position peaked at $859K in Q4 2021.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.